AZTR — Azitra, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1701478 ·
Last close
$0.61
Market Cap
$3.68M
52W High
$3.91
52W Low
$0.52
ADV30
5,449,659
Next earnings
—
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,419,168 -3,347,660 8,916,046 6,727,810 1,581,707
Mar 2026 0 — -3,933,924 -3,927,240 12,126,804 10,051,003 1,646,521
Dec 2025 0 — -2,226,591 -2,233,504 5,025,386 2,068,083 1,224,156
Sep 2025 0 — -2,768,484 -2,764,528 4,300,279 1,401,878 2,021,103

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,105,767
Investing CF
$-279,616
Financing CF
$17,067,461
CapEx
$-279,616
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.27
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-75,796,096
Inventory
—
Receivables
$144,730
ST Investments
—
EBIT TTM
$-12,254,011
Pretax Income TTM
$-12,264,613
Interest Exp TTM
$10,602
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -10,966,665 -10,955,370 5,025,386 1,224,156 3,801,230 -11,224,125
Dec 2024 7,500 -10,985,140 -8,967,492 7,358,802 1,660,504 5,698,298 -10,183,740
Dec 2023 686,000 -7,450,546 -11,283,781 5,115,486 2,202,340 2,913,146 -7,362,375
Dec 2022 284,000 -9,453,604 -10,680,366 7,167,443 43,427,753 -36,260,310 -8,349,469

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-12,272,932
OpCashFlow TTM
—
Assets (Latest)
$8,916,046
Forward EPS
$-0.52

Peers — same industry

TickerNameMarket CapLastDaily %
NCNA NuCana plc $3.70M $0.89 —
XBIO Xenetic Biosciences, Inc. $3.77M $1.61 —
SXTC China SXT Pharmaceuticals, Inc. $3.78M $2.86 —
TRAW Traws Pharma, Inc. $3.59M $0.23 —
PMHS Polomar Health Services, Inc. $3.55M $0.13 —

News headlines (Yahoo Finance, 1h cache)

Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
2026-11-12 21:30 · Yahoo
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models
2026-11-10 13:30 · Yahoo
AZTR: Update on Rash, Fine Lines & Elasticity
2026-11-02 08:00 · Yahoo
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
2026-10-29 12:30 · Yahoo
Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
2026-10-26 12:45 · Yahoo
Azitra, Inc. Announces Reverse Stock Split
2026-10-16 12:00 · Yahoo
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs
2026-09-28 09:32 · Yahoo
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
/C O R R E C T I O N -- Azitra, Inc./
2026-07-15 15:33 · Yahoo
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
2026-07-15 14:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.